The National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) guidelines recommended both EGFR-TKI alone (ET) and ETC as first-line treatments for EGFR-positive NSCLC patients with BM (5, 6). This evidence concerns the gene EGFR and non-small cell lung carcinoma.